Marcin Bielówka
Founder & Chief Executive Officer @ INNOventure
Marcin Bielówka is a seed investor at INNOventure focused on Medical and Health Care.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Marcin Bielówka invests in
Stages Marcin Bielówka invests in
Countries Marcin Bielówka invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 4 (44%)
- Health Care 3 (33%)
- Biotechnology 2 (22%)
- Medical Device 2 (22%)
- Artificial Intelligence 2 (22%)
Stage
- Seed 7 (78%)
- Pre-Seed 2 (22%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Laven helps employers offer complementary health insurance for their employees. | Seed / Sep 01, 2021 | ||
| We are a B2B Marketplace offering full support in printing services for companies around Europe.We deliver high quality print products containing all available print technologies on the market plus creative and product design, print process management with quality staging and logistic for the best Customer Success. We are all-in-one solution forany company, delivering time and cost savings, keeping the high quality production. It's simple, professional, it's easy... just prints me! | $266.1K / Pre-Seed / Nov 26, 2020 | ||
| Neuromedical is a medical device company that supplies electro-stimulating equipment for clinical and therapeutic use. The company provides devices designed to support treatments involving nerve stimulation and pain management. Its products are used by healthcare professionals in various medical settings. Neuromedical focuses on deliveringequipment that meets clinical standards for safety and effectiveness. The company works with institutions and practitioners to support patient care through specialized technology. Its offerings are applications in neuromodulation and rehabilitation. | Seed / May 17, 2020 | ||
| RevDebug is the result of over 20 years of experience creating enterprise level software for large companies. RevDeBug records the entire internal state of a program and enables developers to go back in time to track and fix the root cause of bugs. No such solution has ever existed for Microsoft.NET platform: RevDebug is a true game-changer in theprocess of eliminating bugs, as it turns the current approach completely upside down. It has never been so easy. In fact, for certain bugs it hasn’t even been possible at all. Now it is. RevDebug makes fixing bugs faster. | $475.7K / Seed / May 08, 2020 | ||
| Amorphis Pharma Development specializes in the amorphization and stabilization of pharmaceutical active substances to create drugs. | Seed / Dec 05, 2019 | ||
| Cardiomatics offers cutting-edge, cloud AI-based digital analysis of ECG data. It is a medical-grade system, based on accurate algorithms, ensuring high-quality and trusted outcomes. As a digital health technology developer, Cardiomatics cooperates with physicians, manufacturers, and providers of ECG devices globally. | $304.6K / Pre-Seed / Jul 12, 2019 | ||
| Misje 3000 is a language translation platform that uses artificial intelligence enabling the clients to communicate using a new language. | Seed / Feb 28, 2019 | ||
| SDS Optic specializes in pre-assembling of hermetic and standard photoelectronics components.SDS Optic, headquartered in Lublin, is a highly innovative growing biotech company, focused on development of novel diagnostic strategies in the field of oncology. The company develops and innovates diagnostics solutions, responding to needs of patientswith cancer and focusing on helping the healthcare with faster and less painful diagnostics. | $847.2K / Seed / Dec 21, 2017 | ||
| PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. Due to positive results of clinical trials of TREG method at the University Clinical Center in Gdansk, sharing this breakthrough therapy with as many patients as possible became the main focus of the company.During nearly two years of preparation prior to company’s establishment, business model, commercialization strategy and legal protection of invention were developed together with the University and research team. In July 2015 company was officially established with the participation of University’s special purpose vehicle (SPV), R&D team – patent creators and implementation team, experienced in securing external funding and managing innovative projects.PolTREG is the only entity entitled to implementing the research findings in the area of T-regulatory lymphocytes and using their growth method for clinical use. | Seed / Dec 04, 2015 |
Co-Investors
About INNOventure
INNOventure helps scientists, inventors and entrepreneurs develop business projects based on the results of research and development.
INNOventure Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Marcin Bielówka
Founder & Chief Executive Officer
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Marcin Bielówka invest in?
Marcin Bielówka invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in Poland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Marcin Bielówka?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Marcin Bielówka last invest?
The most recent investment recorded for Marcin Bielówka closed in Sep 2021. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
